Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma.
- DOI
- 10.1093/jjco/hyag146
- Published
- 2026 Sep 16
- Container
- Japanese journal of clinical oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/jjco/hyag146,
title = {Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma.},
author = {Suzuki K and Kosugi H and Ito T and Takamatsu Y and Voorhees PM and Rajkumar SV and Ito M and Sakai C and Takahashi M and Nakatogawa T and Dennis R and Carson R and Dimopoulos MA},
year = {2026},
journal = {Japanese journal of clinical oncology},
doi = {10.1093/jjco/hyag146},
url = {https://doi.org/10.1093/jjco/hyag146}
}RIS
TY - JOUR TI - Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma. AU - Suzuki K AU - Kosugi H AU - Ito T AU - Takamatsu Y AU - Voorhees PM AU - Rajkumar SV AU - Ito M AU - Sakai C AU - Takahashi M AU - Nakatogawa T AU - Dennis R AU - Carson R AU - Dimopoulos MA PY - 2026 JO - Japanese journal of clinical oncology DO - 10.1093/jjco/hyag146 UR - https://doi.org/10.1093/jjco/hyag146 ER -
APA
K, S., H, K., T, I., Y, T., PM, V., SV, R., M, I., C, S., M, T., T, N., R, D., R, C., & MA, D. (2026). Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma.. Japanese journal of clinical oncology. https://doi.org/10.1093/jjco/hyag146
Source records
- pubmed · retrieved 2026-09-25T23:10:55.840Z